This article was downloaded by:


On: 27 January 2011

Access details: Access Details: Free Access

Publisher Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-

41 Mortimer Street, London W1T 3JH, UK



## Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information: http://www.informaworld.com/smpp/title~content=t713597286

## Specific Enzymes Degrading Diadenosine Tetraphosphate (Ap<sub>4</sub> A). Promising Targets for Selective Drugs to be Designed

Andrzej Guranowski; Katedra Biochemii; Akademia Rolnicza

To cite this Article Guranowski, Andrzej , Biochemii, Katedra and Rolnicza, Akademia(1987) 'Specific Enzymes Degrading Diadenosine Tetraphosphate (Ap $_{\rm A}$ A). Promising Targets for Selective Drugs to be Designed', Nucleosides, Nucleotides and Nucleic Acids, 6: 1, 307 - 310

To link to this Article: DOI: 10.1080/07328318708056210 URL: http://dx.doi.org/10.1080/07328318708056210

## PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: http://www.informaworld.com/terms-and-conditions-of-access.pdf

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

SPECIFIC ENZYMES DEGRADING DIADENOSINE TETRAPHOSPHATE (Ap<sub>4</sub>A).

PROMISING TARGETS FOR SELECTIVE DRUGS TO BE DESIGNED.

Andrzej Guranowski, Katedra Biochemii, Akademia Rolnicza, ul. Wożyńska 35, PL-60-637 Poznań, Poland

Abstract. Three types of specific Ap, A-degrading enzymes are known: asymmetrical Ap, A hydrolase, symmetrical Ap, A hydrolase, symmetrical Ap, A hydrolase and Ap, A &, B-phosphorylase (ADP-forming). Since each of the enzymes is specific for different kingdom of the organisms and differs both in the mode of Ap, A degradation, interaction with metal ions and in substrate specificity, one can anticipate that new family of drugs could be designed which would selectively inhibit the microbial (bacterial, fungal or protozoan) enzymes without affecting the mammalian or plant counterparts.

There occur in nature several dinucleoside 5,5'P¹,P³-(or P¹,P⁴-)oligophosphates (DNOPs) but their biological role is poorly understood. Ap4A is the mostly studied
DNOP and it was demonstrated in all organisms investigated.
Basing on the in vitro studies¹-5it is assumed that some aminoacyl-tRNA synthetases are responsible for the synthesis of Ap4A and other adenylylated DNOPs in vivo. So far, Ap4A was shown to be involved in DNA replication 7, activation of some enzymes8.9, and inhibition of others¹0,¹1, functioning of platelets¹2 and regulation of the heat shock response ¹3. Dramatic increase in the level of different DNOPs, both in procaryotic¹4 and eucaryotic¹5cells, has been correlated with stresses. Among the factors which can affect the cellular concentration of DNOPs one has to consider, in addition to the mentioned aminoacyl-tRNA synthetases, the activities of the DNOP-degrading enzymes; these are two unspecific ones, phosphodiesterase I b.17 and nucleotide pyrophosphatase¹8 and the four specific enzymes, Ap3A hydrolase¹6,¹9, asymmetrical Ap4A hydrolase¹6,²0-22, symmetrical Ap4A hydrolase ¹8,²0-25 and Ap4A M.3-phosphorylase²0-27. Properties of the latter three enzymes for which Ap4A was proved to be a preferable substrate are summarized below.

Occurrence of specific Ap4A-degrading enzymes. Asymmetrical Ap4A hydrolase seems to be typical for higher eucaryotes. It was originally found in Artemia salina of then in several mammalian tissues 1,22, as well as in higher plant

308 GURANOWSKI

Lupinus luteus 16. Symmetrical Ap<sub>4</sub>A hydrolase was first reported in slime mold Physarum polycephalum 23 and independently in E. coli and some other bacteria 24,25. Finally, Ap<sub>4</sub>A phosphorylase was found in yeast 26 and recently in Euglena 27.

Mode of Ap4A cleavage and substrate specificity. Asymmetrical Ap4A hydrolase splits Ap4A to AMP plus ATP. Among Ap4A homologs, the Ap3A is not degraded, Ap5A is hydrolyzed to ADP plus ATP, and Ap6A - into 2 ATPs. DNOPs containing other nucleosides than adenosine linked by tetraphosphate chain were proved to be good substrates, too. Mixed dinucleoside tetraphosphates, like Ap4G, were hydrolyzed randomly and ATP, GMP, GTP and AMP were identified as products 16. Also p4A is effectively hydrolyzed to ATP. Symmetrical Ap<sub>4</sub>A hydrolase degrades Ap<sub>4</sub>A into 2 ADPs. Various analogs of Ap<sub>4</sub>A, including Ap<sub>3</sub>A, Ap<sub>5</sub>A, Ap<sub>6</sub>A and p<sub>4</sub>A, act also as substrates and corresponding NDP appears always as one of the reaction products. Ap4A phosphorylase cleaves the substrates phosphorolytically at one of the two & , & -anhydride bonds. The inorganic phosphate is incorporated into the corresponding NDP formed. The yeast phosphorylase does not degrade Ap3A whereas the Euglena enzyme does; into 2 ADPs. Cleavage of Ap5A yields p<sub>4</sub>A plus ADP. In addition, the phosphorylase supports the NDP-P<sub>i</sub> exchange <sup>28</sup>, so it can be used as a tool for the synthesis of NDPs labeled in the  $\mathfrak g$ -position. In the both reactions mentioned, phosphate can be substituted by such anions as arsenate, chromate, molybdate, tungstate or vanadate<sup>29</sup> and then NMP always accumulates as a product of the reactions indicating that an unstable NMP-anion is formed as an intermediate.

Metal cation requirements. Asymmetrical Ap<sub>4</sub>A hydrolase absolutely requires Mg<sup>2+</sup> as the reaction cofactor and among different other cations tested only Mn<sup>2+</sup> supports enzymatic activity albeit to a lower extent than Mg<sup>2+</sup>. Interestingly, Mg<sup>2+</sup> is not effective in the reaction catalyzed by E. colisymmetrical Ap<sub>4</sub>A hydrolase. The enzyme, however, is strongly stimulated by Co<sup>2+</sup> and to some extent by Mn<sup>2+</sup>, Ni<sup>2+</sup> and Cd<sup>2+</sup>. In the hydrolysis of Ap<sub>2</sub>A, Mn<sup>2+</sup> was proved to be 9-fold more effective than Co<sup>2+</sup> 25. Physarum symmetrical Ap<sub>4</sub>A hydrolase can split Ap<sub>4</sub>A and other DNOPs in the absence of metal cations<sup>23</sup>. Phosphorolysis of Ap<sub>4</sub>A catalyzed by the yeast and Euglena Ap<sub>4</sub>A phosphorylases proceeds<sub>2</sub>only in the presence of Mn<sup>2+</sup> or Mg<sup>2+</sup>. Other cations, Co<sup>2+</sup>, Cd<sup>2+</sup> and Ca<sup>2+</sup> are less effective as cofactors. However, the NDP-P<sub>1</sub> exchange and the anionolysis of NDPs do not require the metal cations.

Recently, reports about chemical synthesis of monothio-phosphate-30 and phosphonate31,32 analogs of Ap<sub>4</sub>A (AppppA) were communicated. The following phosphonate analogs: AppCH<sub>2</sub>ppA, ApppCH<sub>2</sub>pA and ApCH<sub>2</sub>ppCH<sub>2</sub>pA were tested as potential substrates and inhibitors of procaryotic and eucaryotic Ap<sub>4</sub>A-degrading enzymes<sup>53</sup>. None of the analogs was cleaved by the <u>E. coli symmetrical</u> Ap<sub>4</sub>A hydrolase and the yeast Ap<sub>4</sub>A phosphorylase cut only ApppCH<sub>2</sub>pA (100-fold slower than Ap<sub>4</sub>A).

The K, values computed in the bacterial system for the analogs are lower than the K value estimated for ApAA (25 µM). This is the first experimental evidence, important from the chemotherapeutic point of view, that specific DNOP-degrading enzymes, particularly those of microbial (bacterial, fungal or protozoan) origin, can be considered as targets for new selective drugs to be designed. Ideal drugs should impair microbial metabolism leaving the mammalian or plant ones not affected.

Acknowledgements. This work was partially supported by Polish Academy of Sciences within Project CPBR 3.13.4.4.4.

## REFERENCES

1 Zamecnik, P. C., Stephenson, M. L., Janeway, C. M. and Randerath, K. (1966) Biochem. Biophys. Res. Commun. <u>24</u>, 91**-**97

2 Randerath, K., Janeway, C. M., Stephenson, M. L. and Zamecnik, P. C. (1966) Biochem. Biophys. Res. Commun. <u>24</u>, 98**-**105

3 Plateau, P., Mayaux, J-F. and Blanquet, S. (1981) Biochemistry 20, 4654-4662

4 Goerlich, O., Foeckler, R. and Holler, E. (1982) Eur. J. Biochem. 126, 135-142
5 Jakubowski, H. (1983) Acta Biochim. Polon. 30, 51-69
6 Grummt, F. (1978) Cold Spring Harbor Symp. Quant. Biol.

<u>43</u>, 649**-**653

7 Rapaport, E., Zamecnik, P. C. and Baril, E. F. (1981) J. Biol. Chem. <u>256</u>, 12148-12151

8 Fernandez, A., Costas, M. J., Sillero, M. A. G. and Sillero, A. (1984) Biochem. Biophys. Res. Commun. <u>121</u>, 155-161

9 Pinto, R. M., Canales, J., Sillero, M. A. G. and Sillero, A. (1986) Biochem. Biophys. Res. Commun. <u>138</u>, 261-267

10 Ono, K., Iwata, Y., Nakamura, H. and Matsukage, A. (1980)

Biochem. Biophys. Res. Commun. 95, 34-40

11 Levy, B. T., Sorge, L. K., Drum, C. C. and Maness, P. F. (1983) Mol. Cell. Biol. 3, 1718-1723

12 Flodgaard, H. and Klenow, H. (1982) Biochem. J. 208, 737**-**742

13 Guedon, G., Sovia, D., Ebel, J-P., Befort, N. and Remy, P. (1985) EMBO J. 4, 3743-3749

14 Lee, Ph. C., Bochner, B. R. and Ames, B. N. (1983) J. Biol. Chem. 258, 6827-6834
15 Brevet, A., Plateau, P., Best-Belpomme, M. and Blanquet, S. (1985) J. Biol. Chem. 260, 15566-15570

16 Jakubowski, H. and Guranowski, A. (1983) J. Biol. Chem. <u>258</u>, 9982**-**9989

17 Cameselle, J. C., Costas, M. J., Sillero, M. A. G. and Sillero, A. (1984) J. Biol. Chem. <u>259</u>, 2879-2885

GURANOWSKI 310

18 Bartkiewicz, M., Sierakowska, H. and Shugar, D. (1984) Eur. J. Biochem. 143, 419-426

19 Lobaton, C. D., Sillero, M. A. G. and Sillero, A. (1975) Biochem. Biophys. Res. Commun. 67, 279-286 20 Warner, A. H. and Finamore, F. J. (1965) Biochemistry

4, 1568-1575

21 Lobaton, C. D., Vallejo, C. G., Sillero, A. and Sillero, M. A. G. (1975) Eur. J. Biochem. <u>50</u>, 495-501
22 Ogilvie, A. and Antl, W. (1983) J. Biol. Chem. <u>258</u>,

4105-4109

23 Barnes, L. D. and Culver, C. A. (1982) Biochemistry 21, 6123-6128

24 Guranowski, A., Jakubowski, H. and Holler, E. (1983)
J. Biol. Chem. 258, 14784-14789

25 Plateau, P., Fromant, M., Brevet, A., Gesquire, A. and Blanquet, S. (1985) Biochemistry 24, 914-922
26 Guranowski, A. and Blanquet, S. (1985) J. Biol. Chem.

<u>260</u>, 3542-3547

27 Guranowski, A., Starzyńska, E. and Wasternack, C. (in preparation)

28 Guranowski, A. and Blanquet, S. (1986) J. Biol. Chem. <u>261</u>, 5943-5946

29 Guranowski, A. and Blanquet, S. (1986) Biochimie 68, 757**-**760

30 Haikal, A. F., Chavis, C. and Imbach, J. L. (1985) Nucleosides and Nucleotides 4, 299

31 Tarussova, N. B., Shumiyanzeva, V. V., Krylov, A. C., Karpeisky, M. Ya. and Khomutov, R. M. (1983) Bioorg. Khim. 9, 838-843

32 Tarussova, N. B., Zavgorodny, C. G. and Osipova, T. I. (1985) Bioorg. Khim. <u>11</u>, 802-807

33 Guranowski, A., Biryukov, A., Tarussova, N. B., Khomutov, R. M. and Jakubowski, H. (in preparation)